Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E18.53 EPS (ttm)18.46 Insider Own0.50% Shs Outstand108.31M Perf Week-4.34%
Market Cap37.05B Forward P/E15.23 EPS next Y22.47 Insider Trans-24.42% Shs Float76.10M Perf Month-9.39%
Income2.12B PEG1.65 EPS next Q5.43 Inst Own73.90% Short Float3.44% Perf Quarter-5.46%
Sales6.37B P/S5.82 EPS this Y70.80% Inst Trans2.17% Short Ratio3.80 Perf Half Y12.83%
Book/sh72.83 P/B4.70 EPS next Y6.43% ROA18.50% Target Price410.05 Perf Year-13.09%
Cash/sh20.24 P/C16.90 EPS next 5Y11.20% ROE25.90% 52W Range281.89 - 416.49 Perf YTD-9.01%
Dividend- P/FCF22.76 EPS past 5Y14.30% ROI22.30% 52W High-18.87% Beta1.36
Dividend %- Quick Ratio3.60 Sales past 5Y33.60% Gross Margin93.40% 52W Low19.87% ATR13.36
Employees6200 Current Ratio4.00 Sales Q/Q10.80% Oper. Margin37.00% RSI (14)35.01 Volatility2.98% 3.95%
OptionableYes Debt/Eq0.00 EPS Q/Q55.70% Profit Margin28.20% Rel Volume1.03 Prev Close342.10
ShortableYes LT Debt/Eq0.09 EarningsNov 06 BMO Payout0.00% Avg Volume687.81K Price337.90
Recom2.60 SMA20-5.94% SMA50-10.86% SMA200-2.81% Volume594,023 Change-1.23%
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Nov-14-18 09:15AM  Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges Zacks
Nov-11-18 08:15AM  ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause PR Newswire
08:14AM  ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause PR Newswire
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-07-18 11:40PM  Edited Transcript of REGN earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
05:07PM  New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial GlobeNewswire
05:01PM  New England Journal of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial PR Newswire
05:00PM  New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial PR Newswire
10:08AM  Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review Zacks
Nov-06-18 04:45PM  Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its Outlook Investor's Business Daily
04:41PM  Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line Zacks
04:05PM  Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript Motley Fool
01:44PM  Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR Zacks
10:39AM  September JOLTS Report In Spotlight Zacks
10:29AM  Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings Zacks
10:09AM  Stocks Rally As Voters Go To The Polls; This Top Stock Breaks Out Investor's Business Daily
08:34AM  Regeneron Pharma Earnings, Revenue beat in Q3
08:00AM  FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis PR Newswire
07:50AM  Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates Zacks
07:23AM  Trump's drug price crack down could squeeze Regeneron and Eylea profits American City Business Journals
07:04AM  The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering Benzinga
06:44AM  Regeneron: 3Q Earnings Snapshot Associated Press
06:30AM  Regeneron Reports Third Quarter 2018 Financial and Operating Results PR Newswire
03:50AM  Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA Reuters
01:16AM  Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies Reuters
01:02AM  FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis GlobeNewswire
12:59AM  FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis PR Newswire
Nov-05-18 02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
02:06PM  Hedge Funds Were Overwhelmingly Bullish On This Stock Insider Monkey
01:19PM  Regeneron Pharmaceuticals Q3 Earnings Preview Benzinga
08:39AM  Why Regeneron (REGN) Might Surprise This Earnings Season Zacks
08:00AM  Three Steps That Help Make This One Of The Best Mutual Funds Investor's Business Daily
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-02-18 10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
Nov-01-18 06:50PM  Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store? Zacks
10:57AM  Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings? Zacks
07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
Oct-31-18 04:52PM  Sanofi (SNY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:27PM  Esperion CEO on safety of new cholesterol drug CNBC Videos
02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-29-18 03:38PM  Drugmakers tout new medicines as eye disease battle intensifies Reuters
12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
09:02AM  The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals Zacks
08:00AM  9 Buffett-Style Stock Picks for a Still-Pricey Stock Market Investopedia
07:43AM  Esperion stock surges 15% on late-stage results for cholesterol drug MarketWatch
07:00AM  Drug Pricing Reform Ideas Don't Affect Our Valuations Morningstar
Oct-26-18 04:02PM  5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings Zacks
07:00AM  Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine PR Newswire
Oct-25-18 06:51PM  Trump seeks to base Medicare drug prices on lower overseas rates Reuters
09:19AM  In 'high risk gambit,' Amgen slashes price of underused cholesterol drug MarketWatch
07:00AM  U.S. FDA declines to approve pre-filled syringe version of Regeneron's Eylea Reuters
07:00AM  EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial PR Newswire
Oct-24-18 06:48PM  Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent Reuters -7.70%
04:06PM  Amgen cuts price of cholesterol drug Repatha by 60 percent Reuters
04:01PM  Amgen cuts price of cholesterol drug by almost 60%, echoing rival's move CNBC
11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks
09:20AM  Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-22-18 08:35AM  Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings? Zacks
07:00AM  FDA Approves Asthma Indication for Dupixent® (dupilumab) PR Newswire
Oct-19-18 08:57PM  Sanofi drug Dupixent wins U.S. FDA approval to treat asthma Reuters
06:03PM  Sanofi drug Dupixent wins U.S. FDA approval to treat asthma Reuters
05:59PM  Sanofi: FDA approves asthma indication for Dupixent® (dupilumab) GlobeNewswire
05:55PM  FDA approves asthsma indication for Dupixent® (dupilumab) PR Newswire
05:55PM  FDA Approves Asthma Indication for Dupixent® (dupilumab) PR Newswire
07:00AM  Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis PR Newswire
Oct-18-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Regeneron (REGN) Zacks
Oct-17-18 09:11AM  Regeneron's Dupixent Meets Goals in Nasal Polyps Studies Zacks
Oct-16-18 12:08PM  4 Strong Stocks to Buy That Double As Big Takeover Targets InvestorPlace +5.55%
08:00AM  Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps PR Newswire
01:20AM  Sanofi, Regeneron say late-stage Dupixent trials show positive results Reuters
01:01AM  Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps GlobeNewswire
12:59AM  Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps PR Newswire
Oct-10-18 11:38AM  5 Healthcare Stocks to Buy for Complete Portfolio Wellness InvestorPlace
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
Oct-08-18 08:45PM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
06:05PM  Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation PR Newswire
05:14PM  3 Top Biotech Stocks to Buy in October Motley Fool
09:30AM  Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018 PR Newswire
Oct-05-18 08:55AM  Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Financial Strength Analysis Simply Wall St.
Oct-03-18 10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
Oct-01-18 04:01PM  Drugmakers are finding new solutions to food allergies CNBC Videos
11:35AM  Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer Zacks
Sep-28-18 05:34PM  Sanofi, Regeneron skin cancer drug gets FDA nod Reuters
05:15PM  Regeneron, Sanofi Win Approval for First Immuno-Oncology Drug Bloomberg
05:05PM  Sanofi, Regeneron skin cancer drug gets FDA nod Reuters
04:51PM  Sanofi, Regeneron have skin-cancer drug approved MarketWatch
04:40PM  FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma PR Newswire
04:39PM  FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
08:30AM  Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals ACCESSWIRE
Sep-27-18 02:46PM  With life-threatening food allergies on the rise, drug companies ramp up new approaches CNBC
01:23PM  Regeneron buys Autotask headquarters for $13.6 million American City Business Journals
09:30AM  Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year? Zacks
Sep-26-18 10:17PM  3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph Motley Fool
09:15AM  My Favorite Large-Cap Biotech Stock to Buy Now Motley Fool
Sep-25-18 10:52AM  FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study Zacks
10:44AM  FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks
09:17AM featured highlights include: Regeneron, AT&T, AMETEK, Hershey Company and BGC Zacks
Sep-24-18 04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
04:00PM  Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar Zacks
Sep-21-18 06:12PM  FDA Confirms Positive Safety Profile of Acadia's Nuplazid Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM